Decreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic Alterations.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2019
2019
Historique:
received:
16
11
2018
accepted:
10
01
2019
entrez:
5
4
2019
pubmed:
5
4
2019
medline:
18
7
2019
Statut:
epublish
Résumé
Histidine-rich glycoprotein (HRG) displays anticoagulant and antifibrinolytic properties in animal models, but its effects in humans are unclear. We investigated serum HRG levels and their associations with the disease stage and prothrombotic alterations in lung cancer (LC) patients. In 148 patients with advanced LC prior to anticancer therapy (87 non-small-cell LC and 61 small-cell LC) versus 100 well-matched controls, we measured HRG levels in association with clot permeability ( Compared to controls, LC patients had 45.9% lower HRG levels with no associations with demographics and comorbidities. Decreased HRG, defined as the 90 Our study is the first to show that decreased HRG levels occur in advanced LC and are associated with the disease stage and hypofibrinolysis.
Sections du résumé
BACKGROUND
BACKGROUND
Histidine-rich glycoprotein (HRG) displays anticoagulant and antifibrinolytic properties in animal models, but its effects in humans are unclear. We investigated serum HRG levels and their associations with the disease stage and prothrombotic alterations in lung cancer (LC) patients.
METHODS
METHODS
In 148 patients with advanced LC prior to anticancer therapy (87 non-small-cell LC and 61 small-cell LC) versus 100 well-matched controls, we measured HRG levels in association with clot permeability (
RESULTS
RESULTS
Compared to controls, LC patients had 45.9% lower HRG levels with no associations with demographics and comorbidities. Decreased HRG, defined as the 90
CONCLUSIONS
CONCLUSIONS
Our study is the first to show that decreased HRG levels occur in advanced LC and are associated with the disease stage and hypofibrinolysis.
Identifiants
pubmed: 30944671
doi: 10.1155/2019/8170759
pmc: PMC6421726
doi:
Substances chimiques
Proteins
0
histidine-rich proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8170759Références
Blood. 2005 Feb 1;105(3):1102-5
pubmed: 15466929
Immunol Cell Biol. 2005 Apr;83(2):106-18
pubmed: 15748207
J Thromb Haemost. 2005 May;3(5):865-72
pubmed: 15869579
Am J Respir Crit Care Med. 2005 Sep 1;172(5):523-9
pubmed: 15961694
J Thromb Haemost. 2008 Apr;6(4):601-8
pubmed: 18208538
Blood. 2009 Nov 5;114(19):4272-8
pubmed: 19690336
Am J Pathol. 2010 Apr;176(4):2039-50
pubmed: 20167858
Thromb Res. 2010 Nov;126(5):426-30
pubmed: 20813396
Blood. 2011 Feb 17;117(7):2093-101
pubmed: 20971949
Cancer Cell. 2011 Jan 18;19(1):31-44
pubmed: 21215706
J Hematol Oncol. 2011 Apr 14;4:15
pubmed: 21489304
Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):e88-99
pubmed: 21836064
Cancer Res. 2012 Apr 15;72(8):1953-63
pubmed: 22374984
PLoS One. 2012;7(7):e40033
pubmed: 22808089
J Proteome Res. 2012 Sep 7;11(9):4541-52
pubmed: 22827608
Thromb Res. 2013 Mar;131(3):262-7
pubmed: 23273404
Neoplasma. 2014;61(1):17-26
pubmed: 24195504
Anticancer Res. 2014 Feb;34(2):593-603
pubmed: 24510988
Med Oncol. 2014 Apr;31(4):897
pubmed: 24567057
Thromb Haemost. 2014 Jul 3;112(1):32-42
pubmed: 24671700
Eur J Clin Invest. 2014 Jun;44(6):557-66
pubmed: 24738991
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Thromb Haemost. 2015 Nov 25;114(6):1251-9
pubmed: 26293709
Multidiscip Respir Med. 2015 Sep 15;10(1):28
pubmed: 26380084
Clin Exp Allergy. 2016 Jul;46(7):932-44
pubmed: 27019085
Surg Oncol Clin N Am. 2016 Jul;25(3):439-45
pubmed: 27261907
Pol Arch Intern Med. 2017 Dec 22;127(12):873-881
pubmed: 29225327
Pol Arch Intern Med. 2018 Aug 31;128(7-8):462-468
pubmed: 30057372
Sci Rep. 2018 Nov 23;8(1):17301
pubmed: 30470809
J Thorac Dis. 2018 Dec;10(12):6863-6872
pubmed: 30746232
Biochem Med Metab Biol. 1986 Oct;36(2):210-3
pubmed: 3778686
J Clin Invest. 1986 Apr;77(4):1305-11
pubmed: 3958188
Hoppe Seylers Z Physiol Chem. 1972 Dec;353(12):1841-9
pubmed: 4631012
J Biol Chem. 1983 Mar 25;258(6):3803-8
pubmed: 6833231
CA Cancer J Clin. 1998 May-Jun;48(3):167-76; discussion 164-6
pubmed: 9594919